Clinical study on treatment of spontaneous cerebral hemorrhage with Defetoxamine

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007394

Enrollment

Unknown

Registered

2015-11-10

Start date

2016-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial hemorrhage

Interventions

Intervention group:use Defetoxamine

Control:blank

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) over 18 years old; (2) patients with spontaneous intracranial hemorrhage; (3) supratentorial hemorrhage; (4) bleeding capacity 10-30ml; (5) bleeding within 8 hours before admission; (6) GCS>12.

Exclusion criteria

Exclusion criteria: (1) Traumatic hemorrhage; (2) hemorrhage due to AVM, aneurysm or tumor; (3) unable to undergo MR exam; (4) Used to receive Defetoxamine therapy; (5) Renal function comprimised (Cr over 2mg/dl); (6) Iron-deficiency anemia; (7) indication for surgery; (8) Heart function comprimised; (9) pregnent; (10) expected survival less than 90 days.

Design outcomes

Primary

Measure	Time frame
decrease of hemorrhage volum;	—

Secondary

Measure	Time frame
Vital sign;Plasma ferritin, transferrin;	—

Countries

China

Contacts

Public ContactGang Wu

15197533@qq.com13918187967

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026